A study of more than 229,000 obese adults without diabetes in the United States has shown that weight loss drugs are associated with a decreased risk of obesity-related cancers. The research found that GLP-1 receptor agonists (GLP-1 RAs), such as semaglutide (brand names: Ozempic, Wegovy) and tirzepatide (brand names: Mounjaro and Zepbound), were associated with a 41% decrease in the overall risk of developing cancer among non-diabetic patients who used the drugs for weight management, compared to those who relied on diet and exercise alone.
from Medical Xpress - latest medical and health news stories https://ift.tt/t2a97lp
